Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung-Reference-Cited by-同舟云学术

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung

Published:2008-01 Issue:1 Volume:59 Page:111-118
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Kim Young Tae,Kim Tae-you,Lee Dong Soon,Park Sun Jung,Park Ju-yeon,Seo Soon-Jung,Choi Hyo-Seon,Kang Hee Jung,Hahn Seokyung,Kang Chang Hyun,Sung Sook Whan,Kim Joo Hyun

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types;Baselga;J Clin Oncol,2002

2. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial;Herbst;J Clin Oncol,2002

3. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer;Raben;Semin Oncol,2002

4. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors;Nakagawa;Ann Oncol,2003

5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner;Cancers;2022-03-23

2. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features;The Journal of Thoracic and Cardiovascular Surgery;2022-01

3. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy;Clinical Lung Cancer;2021-11

4. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma;The Journal of Thoracic and Cardiovascular Surgery;2021-09

5. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism‐related genes;Cancer Cell International;2021-04-15